We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. Given this risk, we thought we'd take a look at whether Immunovant NASDAQ:IMVT ) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. Check out our latest analysis for Immunovant When Might Immunovant Run Out Of Money? A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In September 2024, Immunovant had US$473m in cash, and was debt-free. In the last year, its cash burn
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant, Inc. (NASDAQ: IMVT) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.MarketBeat
- Immunovant price target lowered to $45 from $47 at Wells Fargo [Yahoo! Finance]Yahoo! Finance
- Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Wells Fargo & Company from $47.00 to $45.00. They now have an "overweight" rating on the stock.MarketBeat
- FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial [Yahoo! Finance]Yahoo! Finance
- Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024PR Web
IMVT
Earnings
- 8/6/24 - Miss
IMVT
Sec Filings
- 12/18/24 - Form 4
- 12/18/24 - Form 3
- 12/4/24 - Form 4
- IMVT's page on the SEC website